Evidence map›Paper›PMID 39188946›Full record

ReviewFrontiers in pharmacology2024

Pharmacological effects and the related mechanism of scutellarin on inflammation-related diseases: a review.

Yang Zhou, Chenlin Gu, Yan Zhu, Yuting Zhu, Yutong Chen, Li Shi, Yang Yang, Xin Lu, Hanqing Pang

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. [Scutellarin improves metabolic dysfunction-associated steatotic liver disease in rats by regulating MMP7 and LCN2].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. FermentedFrontiers in veterinary science · 2025
    Article
  9. Review
  10. Anti-Inflammatory Effect of Extract fromJournal of microbiology and biotechnology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yang Zhou *School of Medicine, Institute of Translational Medicine, Yangzhou University, Yangzhou, China.
Chenlin Gu *School of Medicine, Institute of Translational Medicine, Yangzhou University, Yangzhou, China.
Yan Zhu *School of Medicine, Institute of Translational Medicine, Yangzhou University, Yangzhou, China.
Yuting ZhuSchool of Medicine, Institute of Translational Medicine, Yangzhou University, Yangzhou, China.
Yutong ChenSchool of Medicine, Institute of Translational Medicine, Yangzhou University, Yangzhou, China.
Li ShiSchool of Medicine, Institute of Translational Medicine, Yangzhou University, Yangzhou, China.
Yang YangSchool of Medicine, Institute of Translational Medicine, Yangzhou University, Yangzhou, China.
Xin LuSchool of Medicine, Institute of Translational Medicine, Yangzhou University, Yangzhou, China.
Hanqing PangSchool of Medicine, Institute of Translational Medicine, Yangzhou University, Yangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation is a biological response of multicellular organisms caused by injuries, pathogens or irritants. An excessive inflammatory response can lead to tissue damage and various chronic diseases. Chronic inflammation is a common feature of many diseases, making the search for drugs to treat inflammation-related diseases urgent. Scutellarin, a natural flavonoid metabolite, is widely used in the treatment of various inflammation-related diseases for its anti-inflammatory, anti-oxidant and anti-cancer activities. Scutellarin can inhibit key inflammatory pathways (PI3K/Akt, MAPK, and NF-κB, etc.) and activate the anti-oxidant related pathways (Nrf2, ARE, ect.), thereby protecting tissues from inflammation and oxidative stress. Modern extraction technologies, such as microwave-assisted, ultrasound assisted, and supercritical fluid extraction, have been utilized to extract scutellarin from Scutellaria and Erigeron genera. These technologies improve efficiency and retain biological activity, making scutellarin suitable for large-scale production. Scutellarin has significant therapeutic effects in treating osteoarthritis, pulmonary fibrosis, kidney injury, and cardiovascular diseases. However, due to its low bioavailability and short half-life, its clinical application is limited. Researchers are exploring innovative formulations (β-cyclodextrin polymers, triglyceride mimetic active ingredients, and liposome precursors, etc.) to improve stability and absorption rates. Despite these challenges, the potential of scutellarin in anti-inflammatory, anti-oxidant, and anti-cancer applications remains enormous. By optimizing formulations, exploring combination therapies, and conducting in-depth mechanistic research, scutellarin can play an important role in treating various inflammatory diseases, providing patients with more and effective treatment options.

Indexed as

inflammationMAPKNF-κBNrf2/AREPI3K/AKTscutellarin

Identifiers

PMID39188946
PMCPMC11345237

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.